Pulmonary Embolism in Hospitalized Patient with Coronavirus Disease 2019 (COVID-19)

Wulyo Rajabto, Dimas Priantono, Rahmad Mulyadi

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Coronavirus disease 2019 (COVID-19) has been a global pandemic for over a year. Meanwhile, thrombosis occurs in up to one-third of hospitalized patients with the disease, while pulmonary embolism has been reported to be the most dangerous thrombosis which greatly increases mortality in COVID-19.Hospitalized patients with COVID-19 are at high risk of thromboembolic complications such as deep vein thrombosis and pulmonary embolism. The hypercoagulable state caused by COVID-19 leads to activation of coagulation cascade, meanwhile, CT pulmonary angiography is used to diagnose or exclude pulmonary embolism. Furthermore, ground-glass opacities are also evaluated using this modality. Low molecular weight heparin is the anticoagulant of choice due to simplicity in administration and low risk of drug-drug interactions.Pulmonary embolism occurs in COVID-19 patients without DVT. Based on the results, parenteral anticoagulant followed by DOAC is the mainstay of treatment in COVID-19 coagulopathy.

Original languageEnglish
Pages (from-to)493-496
Number of pages4
JournalActa medica Indonesiana
Volume53
Issue number4
Publication statusPublished - 1 Oct 2021

Keywords

  • COVID-19
  • pulmonary embolism
  • thrombosis

Fingerprint

Dive into the research topics of 'Pulmonary Embolism in Hospitalized Patient with Coronavirus Disease 2019 (COVID-19)'. Together they form a unique fingerprint.

Cite this